A 7–34 analog of the parathyroid hormone-related protein has potent antagonist and partial agonist activity in vivo

Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients

“…dominance of circulating active PTH-(1-84) over the and large C-PTH fragments by parathyroid glands. Pre-84) action on bone, and extend preclinical observations vailing serum calcium levels at time of blood sampling [24,[32][33][34][35][36] to the dialysis population. The wide range of did not have an impact on the diagnostic value of the the obtained results in the PTH-(1-84)/C-PTH fragment different PTH peptides.…”

“…Protocol Because the large C-PTH fragments contain portions of PTH essential for binding to either the PTH-1 receptor After signing the consent form, patients were scheduled to undergo an iliac crest bone biopsy. Before bone [24,[32][33][34][35][36] or the C-PTH receptor [13,[25][26][27][28][29][30][31], the large C-PTH fragments have the potential to antagonize PTH-biopsy, patients received double tetracycline labeling of bone as previously described [37]. During the week be-(1-84) action on bone.…”

PTH Signaling During Exercise Contributes to Bone Adaptation

“…The use of PTH to inhibit the cellular response to PTH or PTH-rP in bone has been widely used and demonstrated to not alter systemic PTH levels or urinary secretion of calcium, phosphorus, and adenosine 3 0 ,5 0 -cyclic monophosphate. (51)(52)(53)(54) In conclusion, exercise subjects bone to increased dynamic loading and PTH levels, both of which are key stimulants for bone adaptation. In this study we demonstrated that PTH signaling during exercise increases trabecular bone formation with a platelike structure and improves structural-level mechanical properties of cortical bone, whereas tissue-level properties are modified independent of PTH signaling during exercise.…”

“…Despite this limitation, we demonstrated that bone adaptation in response to exercise is influenced by PTH‐mediated or PTH‐rP–mediated signaling. The use of PTH(7‐34) to inhibit the cellular response to PTH or PTH‐rP in bone has been widely used and demonstrated to not alter systemic PTH levels or urinary secretion of calcium, phosphorus, and adenosine 3′,5′‐cyclic monophosphate …”

Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells

“…However, it was possible that the PTHrP peptides we tested were not representative of those produced by prostatic cells, so we next attempted to block potential growth-regulatory activity of endogenous PTHrP with the antagonist PTHrP 7-34. This peptide binds to the parathyroid hormone (PTH)/PTHrP receptor, but does not activate the receptor, and therefore PTHrP 7-34 is widely used as a competitive antagonist [19]. We first tested PTHrP 7-34 in clonal growth assays and determined that it did not alter growth at concentrations up to 100 nM (not shown).…”